Converd Overview
- Year Founded
-
2011
- Status
-
Private
- Employees
-
41
- Latest Deal Type
-
2ndary - Private
- Investors
-
8
Converd General Information
Description
Operator of a research and development platform for novel oncolytic virus therapies intended for the immune system's ability to target and destroy cancer cells. The company offers a comprehensive pipeline built on multiple virus-engineering platforms, enabling integration with immune cell therapies and checkpoint inhibitors, allowing oncologists and researchers to explore combination regimens that aim to convert non-responsive tumors into immunologically active ones and advance potential treatments for a range of cancer patients.
Contact Information
Website
www.converd.com.cnCorporate Office
- 7th Floor, Building D-1, Number 2959 Yuhangtang Road, Future Science and Technology City
- Yuhang District
- Hangzhou, Zhejiang 311121
- China
Corporate Office
- 7th Floor, Building D-1, Number 2959 Yuhangtang Road, Future Science and Technology City
- Yuhang District
- Hangzhou, Zhejiang 311121
- China
Converd Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 11. Secondary Transaction - Private | 22-Dec-2025 | Completed | Generating Revenue | |||
| 10. Later Stage VC | 23-Sep-2024 | Completed | Generating Revenue | |||
| 9. Secondary Transaction - Private | 20-Dec-2022 | Completed | Generating Revenue | |||
| 8. Later Stage VC (Series C) | 02-Aug-2022 | Completed | Generating Revenue | |||
| 7. Secondary Transaction - Private | 24-Jun-2022 | Completed | Generating Revenue | |||
| 6. Later Stage VC | 29-Oct-2021 | Completed | Generating Revenue | |||
| 5. Secondary Transaction - Private | 01-Feb-2021 | Completed | Generating Revenue | |||
| 4. Later Stage VC (Series B) | 15-Dec-2017 | Completed | Generating Revenue | |||
| 3. Later Stage VC | 28-Sep-2017 | Completed | Generating Revenue | |||
| 2. Later Stage VC | 18-Jul-2017 | Completed | Generating Revenue |
Converd Patents
Converd Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| WO-2026158643-A1 | Therapeutic agent comprising recombinant oncolytic vaccinia virus and antibody-drug conjugate and use thereof | Pending | 27-Jan-2025 | ||
| WO-2022057725-A1 | Isolated oncolytic adenovirus capable of expressing exogenous gene, vector, therapeutic agent, and use | Inactive | 16-Sep-2020 | ||
| EP-4162941-A1 | Isolated recombinant oncolytic poxvirus capable of being regulated and controlled by microrna and use thereof | Pending | 30-Apr-2020 | ||
| EP-4162941-A4 | Isolated recombinant oncolytic poxvirus capable of being regulated and controlled by microrna and use thereof | Pending | 30-Apr-2020 | ||
| US-20230265396-A1 | Isolated recombinant oncolytic poxvirus capable of being regulated and controlled by microrna and use thereof | Pending | 30-Apr-2020 | C12N7/00 |
Converd Signals
Converd Investors (8)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Hangzhou Huafang Chuanghuang Investment Management | Corporate Venture Capital | Minority | ||
| Holley Group | Corporation | Minority | ||
| Lanson Investment | Growth/Expansion | Minority | ||
| Betta Pharmaceuticals | Corporation | Minority | ||
| CR Life Sciences | Corporation | Minority |
Converd FAQs
-
When was Converd founded?
Converd was founded in 2011.
-
Where is Converd headquartered?
Converd is headquartered in Hangzhou, China.
-
What is the size of Converd?
Converd has 41 total employees.
-
What industry is Converd in?
Converd’s primary industry is Enterprise Systems (Healthcare).
-
Is Converd a private or public company?
Converd is a Private company.
-
What is Converd’s current revenue?
The current revenue for Converd is .
-
Who are Converd’s investors?
Hangzhou Huafang Chuanghuang Investment Management, Holley Group, Lanson Investment, Betta Pharmaceuticals, and CR Life Sciences are 5 of 8 investors who have invested in Converd.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process